The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/show/NCT02149108




Registration number
NCT02149108
Ethics application status
Date submitted
26/05/2014
Date registered
29/05/2014
Date last updated
21/07/2017

Titles & IDs
Public title
Nintedanib (BIBF 1120) vs Placebo in Refractory Metastatic Colorectal Cancer (LUME-Colon 1)
Scientific title
A Double-blind, Randomised, Placebo Controlled Phase III Study of Nintedanib Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Patients With Metastatic Colorectal Cancer Refractory to Standard Therapies.
Secondary ID [1] 0 0
2012-000095-42
Secondary ID [2] 0 0
1199.52
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Colorectal Neoplasms 0 0
Condition category
Condition code
Cancer 0 0 0 0
Bowel - Back passage (rectum) or large bowel (colon)

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Nintedanib (BIBF 1120)
Treatment: Drugs - Placebo
Treatment: Drugs - BSC
Treatment: Drugs - BSC

Experimental: Nintedanib (BIBF 1120) + BSC -

Placebo Comparator: Placebo + BSC -


Treatment: Drugs: Nintedanib (BIBF 1120)


Treatment: Drugs: Placebo


Treatment: Drugs: BSC


Treatment: Drugs: BSC


Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Progression-Free Survival (PFS) by Central Review Assessment - PFS by central review assessment was defined as the time from the date of randomisation to the date of disease progression according to Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1 or death from any cause, whichever occurred first.
Median, 95% Confidence Interval were calculated from an unadjusted Kaplan-Meier curve for each treatment arm.
Timepoint [1] 0 0
From randomisation until cut-off date 14JUN2016.
Primary outcome [2] 0 0
Overall Survival (OS) - OS was defined as the time from randomisation to the time of death from any cause.
Median, 95% Confidence Interval were calculated from an unadjusted Kaplan-Meier curve for each treatment arm.
Timepoint [2] 0 0
From randomisation until cut-off date 14JUN2016.
Secondary outcome [1] 0 0
Objective Tumour Response (Complete Response (CR)) + Partial Response (PR) by Central Review Assessment - Objective tumour response was defined as best overall response of CR or PR determined by central review assessment.
Timepoint [1] 0 0
From randomisation until cut-off date 14JUN2016.
Secondary outcome [2] 0 0
Disease Control (Complete Response + Partial Response + Stable Disease) by Central Review Assessment - Disease control was defined as best overall response of CR, PR, or Stable Disease (SD).
Timepoint [2] 0 0
From randomisation until cut-off date 14JUN2016.

Eligibility
Key inclusion criteria
Inclusion criteria:

- Age >= 18 years

- Signed informed consent

- Histologically or cytologically confirmed colorectal adenocarcinoma

- Metastatic or locally advanced disease not amenable to curative surgery and/or
radiotherapy

- Eastern Cooperative Oncology Group (ECOG) performance status = 1

- At least one measurable lesion according to Response Evaluation Criteria In Solid
Tumours (RECIST) version 1.1

- Progression on standard therapies or withdrawn from standard treatment due to
unacceptable toxicity. Previous standard treatment must include all of the following:

- - fluoropyrimidine

- - oxaliplatin: Patients treated with oxaliplatin in adjuvant setting should have
progressed within 6 months of completion of adjuvant therapy or they must have been
treated with oxaliplatin for metastatic disease

- - irinotecan

- - bevacizumab or aflibercept

- - cetuximab or panitumumab for patients with K-Ras wt or Ras wt tumours

- - The remaining standard available therapy as recommended by investigator is best
supportive care (note: previous treatment with regorafenib and TAS 102 are allowed and
these agents should be administered before study if available to patient according to
local standards)

- - Life expectancy of at least 12 weeks

- - Hepatic function: aspartate aminotransferase (AST)/ Alanine Amino Transferase (ALT)
= 1.5 X Upper Limit of Normal (ULN) and bilirubin = ULN for patients without liver
metastases. AST/ALT = 2.5 X ULN and bilirubin = ULN for patients with liver
metastases. Patients with Gilbert syndrome and bilirubin < 2 X ULN and normal AST/ALT
are eligible

- Coagulation parameters: International normalised ratio (INR) < 2 and partial
prothrombin Time (PTT) = 2xULN
Minimum age
18 Years
Maximum age
No limit
Gender
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
Exclusion criteria:

- Previous treatment with nintedanib

- toxicity attributed to previous anticancer therapy that did not resolve to Common
Terminology Criteria for Adverse Events (CTCAE) grade =1

- History of other malignancies in the last 5 years, in particular those that could
interfere with interpretation of results.

- Serious concomitant disease or medical condition affecting compliance with trial
requirements or which are considered relevant for the evaluation of the efficacy or
safety of the trial drug,

- Significant cardiovascular diseases

- History of severe haemorrhagic or thromboembolic event in the past 12 months

- Bleeding or thrombotic disorders requiring anticoagulant therapy such as warfarin, or
similar agents requiring therapeutic INR monitoring

- Gastrointestinal disorders or abnormalities that would interfere with absorption of
study drug

- Patient with brain metastases that are symptomatic and/or require therapy.

- Patients of childbearing potential who are sexually active and unwilling to use a
highly effective method of contraception

- Pregnancy or breast-feeding.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint(s)
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,VIC,WA
Recruitment hospital [1] 0 0
1199.52.6102 Boehringer Ingelheim Investigational Site - Concord
Recruitment hospital [2] 0 0
1199.52.6103 Boehringer Ingelheim Investigational Site - St Leonards
Recruitment hospital [3] 0 0
1199.52.6101 Boehringer Ingelheim Investigational Site - Wollongong
Recruitment hospital [4] 0 0
1199.52.6104 Boehringer Ingelheim Investigational Site - Heidelberg
Recruitment hospital [5] 0 0
1199.52.6105 Boehringer Ingelheim Investigational Site - Nedlands
Recruitment hospital [6] 0 0
1199.52.6106 Boehringer Ingelheim Investigational Site - Perth
Recruitment postcode(s) [1] 0 0
- Concord
Recruitment postcode(s) [2] 0 0
- St Leonards
Recruitment postcode(s) [3] 0 0
- Wollongong
Recruitment postcode(s) [4] 0 0
- Heidelberg
Recruitment postcode(s) [5] 0 0
- Nedlands
Recruitment postcode(s) [6] 0 0
- Perth
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
California
Country [2] 0 0
United States of America
State/province [2] 0 0
Connecticut
Country [3] 0 0
United States of America
State/province [3] 0 0
Illinois
Country [4] 0 0
United States of America
State/province [4] 0 0
Iowa
Country [5] 0 0
United States of America
State/province [5] 0 0
Kansas
Country [6] 0 0
United States of America
State/province [6] 0 0
Louisiana
Country [7] 0 0
United States of America
State/province [7] 0 0
Michigan
Country [8] 0 0
United States of America
State/province [8] 0 0
Nebraska
Country [9] 0 0
United States of America
State/province [9] 0 0
New York
Country [10] 0 0
United States of America
State/province [10] 0 0
Ohio
Country [11] 0 0
United States of America
State/province [11] 0 0
Tennessee
Country [12] 0 0
United States of America
State/province [12] 0 0
Texas
Country [13] 0 0
Argentina
State/province [13] 0 0
Cdad. de Córdoba
Country [14] 0 0
Argentina
State/province [14] 0 0
Ciudad Autónoma de Bs As
Country [15] 0 0
Austria
State/province [15] 0 0
Linz
Country [16] 0 0
Austria
State/province [16] 0 0
Wien
Country [17] 0 0
Belgium
State/province [17] 0 0
Aalst
Country [18] 0 0
Belgium
State/province [18] 0 0
Bonheiden
Country [19] 0 0
Belgium
State/province [19] 0 0
Bruxelles
Country [20] 0 0
Belgium
State/province [20] 0 0
Charleroi
Country [21] 0 0
Belgium
State/province [21] 0 0
Edegem
Country [22] 0 0
Belgium
State/province [22] 0 0
Haine-Saint-Paul
Country [23] 0 0
Belgium
State/province [23] 0 0
Leuven
Country [24] 0 0
Belgium
State/province [24] 0 0
Liège
Country [25] 0 0
Belgium
State/province [25] 0 0
Luxembourg
Country [26] 0 0
Canada
State/province [26] 0 0
British Columbia
Country [27] 0 0
Canada
State/province [27] 0 0
Ontario
Country [28] 0 0
Canada
State/province [28] 0 0
Quebec
Country [29] 0 0
Czechia
State/province [29] 0 0
Brno
Country [30] 0 0
Czechia
State/province [30] 0 0
Hradec Kralove
Country [31] 0 0
Czechia
State/province [31] 0 0
Prague
Country [32] 0 0
Denmark
State/province [32] 0 0
Herning
Country [33] 0 0
Denmark
State/province [33] 0 0
København Ø
Country [34] 0 0
Denmark
State/province [34] 0 0
Næstved
Country [35] 0 0
Denmark
State/province [35] 0 0
Odense C
Country [36] 0 0
France
State/province [36] 0 0
Lille cedex
Country [37] 0 0
France
State/province [37] 0 0
Lyon cedex 8
Country [38] 0 0
France
State/province [38] 0 0
Paris cedex 15
Country [39] 0 0
France
State/province [39] 0 0
Reims Cedex
Country [40] 0 0
Germany
State/province [40] 0 0
Dresden
Country [41] 0 0
Germany
State/province [41] 0 0
Essen
Country [42] 0 0
Germany
State/province [42] 0 0
Freiburg
Country [43] 0 0
Germany
State/province [43] 0 0
Mannheim
Country [44] 0 0
Germany
State/province [44] 0 0
Ulm
Country [45] 0 0
Hong Kong
State/province [45] 0 0
Hong Kong
Country [46] 0 0
Israel
State/province [46] 0 0
Beer Sheva
Country [47] 0 0
Israel
State/province [47] 0 0
Petach Tikva
Country [48] 0 0
Israel
State/province [48] 0 0
Tel Aviv
Country [49] 0 0
Italy
State/province [49] 0 0
Genova
Country [50] 0 0
Italy
State/province [50] 0 0
Milano
Country [51] 0 0
Italy
State/province [51] 0 0
Napoli
Country [52] 0 0
Italy
State/province [52] 0 0
Padova
Country [53] 0 0
Italy
State/province [53] 0 0
Pisa
Country [54] 0 0
Italy
State/province [54] 0 0
San Giovanni Rotondo (FG)
Country [55] 0 0
Japan
State/province [55] 0 0
Aichi, Nagoya
Country [56] 0 0
Japan
State/province [56] 0 0
Chiba, Chiba
Country [57] 0 0
Japan
State/province [57] 0 0
Chiba, Kashiwa
Country [58] 0 0
Japan
State/province [58] 0 0
Ehime, Matsuyama
Country [59] 0 0
Japan
State/province [59] 0 0
Fukuoka, Fukuoka
Country [60] 0 0
Japan
State/province [60] 0 0
Hokkaido, Sapporo
Country [61] 0 0
Japan
State/province [61] 0 0
Hyogo, Amagasaki
Country [62] 0 0
Japan
State/province [62] 0 0
Hyogo, Kobe
Country [63] 0 0
Japan
State/province [63] 0 0
Ibaraki, Tsukuba
Country [64] 0 0
Japan
State/province [64] 0 0
Oita, Yufu
Country [65] 0 0
Japan
State/province [65] 0 0
Osaka, Osaka
Country [66] 0 0
Japan
State/province [66] 0 0
Osaka, Suita
Country [67] 0 0
Japan
State/province [67] 0 0
Saitama, Kitaadachi-gun
Country [68] 0 0
Japan
State/province [68] 0 0
Shizuoka, Sunto-gun
Country [69] 0 0
Japan
State/province [69] 0 0
Tokyo , Shinagawa-ku
Country [70] 0 0
Japan
State/province [70] 0 0
Tokyo, Koto-ku
Country [71] 0 0
Korea, Republic of
State/province [71] 0 0
Goyang
Country [72] 0 0
Korea, Republic of
State/province [72] 0 0
Seoul
Country [73] 0 0
Mexico
State/province [73] 0 0
Mexico
Country [74] 0 0
Netherlands
State/province [74] 0 0
Amsterdam
Country [75] 0 0
Netherlands
State/province [75] 0 0
Utrecht
Country [76] 0 0
Poland
State/province [76] 0 0
Jelenia Gora
Country [77] 0 0
Poland
State/province [77] 0 0
Poznan
Country [78] 0 0
Poland
State/province [78] 0 0
Wroclaw
Country [79] 0 0
Portugal
State/province [79] 0 0
Almada
Country [80] 0 0
Portugal
State/province [80] 0 0
Coimbra
Country [81] 0 0
Portugal
State/province [81] 0 0
Loures
Country [82] 0 0
Portugal
State/province [82] 0 0
Porto
Country [83] 0 0
Russian Federation
State/province [83] 0 0
Moscow
Country [84] 0 0
Russian Federation
State/province [84] 0 0
St. Petersburg
Country [85] 0 0
Russian Federation
State/province [85] 0 0
Tyumen
Country [86] 0 0
Spain
State/province [86] 0 0
Barcelona
Country [87] 0 0
Spain
State/province [87] 0 0
L'Hospitalet de Llobregat
Country [88] 0 0
Spain
State/province [88] 0 0
La Coruña
Country [89] 0 0
Spain
State/province [89] 0 0
Madrid
Country [90] 0 0
Spain
State/province [90] 0 0
Santander
Country [91] 0 0
Spain
State/province [91] 0 0
Sevilla
Country [92] 0 0
Sweden
State/province [92] 0 0
Stockholm
Country [93] 0 0
Sweden
State/province [93] 0 0
Uppsala
Country [94] 0 0
Taiwan
State/province [94] 0 0
Kaohsiung
Country [95] 0 0
Taiwan
State/province [95] 0 0
Taipei
Country [96] 0 0
Taiwan
State/province [96] 0 0
Taoyuan County
Country [97] 0 0
Turkey
State/province [97] 0 0
Adana
Country [98] 0 0
Turkey
State/province [98] 0 0
Ankara
Country [99] 0 0
Turkey
State/province [99] 0 0
Antalya
Country [100] 0 0
Turkey
State/province [100] 0 0
Istanbul
Country [101] 0 0
Turkey
State/province [101] 0 0
Izmir
Country [102] 0 0
United Kingdom
State/province [102] 0 0
Aberdeen
Country [103] 0 0
United Kingdom
State/province [103] 0 0
Manchester
Country [104] 0 0
United Kingdom
State/province [104] 0 0
Middlesex
Country [105] 0 0
United Kingdom
State/province [105] 0 0
Nottingham
Country [106] 0 0
United Kingdom
State/province [106] 0 0
Southampton

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Boehringer Ingelheim
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The objective of this Phase III study is to evaluate the efficacy of nintedanib in patients
with metastatic colorectal cancer (mCRC) after failure of previous treatment with standard
chemotherapy and biological agents.
Trial website
https://clinicaltrials.gov/show/NCT02149108
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Boehringer Ingelheim
Address 0 0
Boehringer Ingelheim
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

Summary results
Other publications